NCT03558061已完成2 期
A Single Arm Open-Label Study to Evaluate the Therapeutic Effects and Safety of a 6-Week Treatment Regimen of ALK4290 in Patients With Newly Diagnosed Wet Age-Related Macular Degeneration (wAMD)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 5
- 主要终点
- Best Corrected Visual Acuity (BCVA)
研究概览
简要总结
This study will evaluate the therapeutic effects and safety of 800 mg ALK4290 administered daily over a 6-week dosing period in newly diagnosed patients with wet age-related macular degeneration (wAMD).
详细描述
This study is designed to evaluate the therapeutic effects and safety of oral ALK4290 administered at 800 mg daily over a 6-week dosing period in newly diagnosed (treatment naïve) patients with wAMD. The study agent will be orally self-administered. All subjects will receive the study agent, ALK4290. This study does not contain a placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women with newly diagnosed active CNV secondary to AMD, diagnosed by a retinal specialist with all the following characteristics and ophthalmic inclusion criteria applied to the study eye:
- •No prior treatment for wAMD in the study eye and no current or planned concomitant intravitreal anti-VEGF treatment in the fellow eye
- •Central subfield retinal thickness ≥ 250 microns on SD-OCT (exclusive of subretinal pigment epithelial fluid, inclusive of SRF)
- •Presence of SRF and/or IRF on SD-OCT
- •Any active CNV with subfoveal leakage as determined by FA
- •Total lesion size not greater than 12 disc areas on FA
- •If present, subretinal hemorrhage must comprise < 50% of the total lesion area on FA
- •No subfoveal fibrosis or atrophy on FA
- •BCVA letter score, as measured by ETDRS in the study eye, between 70 and 24 letters, inclusive, at screening
- •Patients 50 years of age or older at screening visit 1
- •Body mass index (BMI) between18 and ≤ 40 at screening visit 1
- •Female subjects must not be pregnant or breastfeeding. Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry.
- •Signed informed consent consistent with ICH-GCP guidelines and local legislation prior to participation in the trial, which includes medication washout and restrictions
排除标准
- •Previous participation in any studies of investigational drugs within 1 month preceding screening visit
- •Any form of macular degeneration that is not age-related (e.g., Best's disease, Stargardt's disease, Sorsby's disease, etc.)
- •Additional eye disease in the study eye that could compromise BCVA (i.e., uncontrolled glaucoma (intraocular pressure > 24) with visual field loss, clinically significant diabetic maculopathy, history of ischemic optic neuropathy or retinal vascular occlusion, vitreomacular traction, monocular vision, or genetic disorders such as retinitis pigmentosa; high myopia > 8 diopters)
- •The presence of polypoidal choroidal vasculopathy (PCV) or retinal angiomatous proliferation (RAP) in the study eye
- •Anterior segment and vitreous abnormalities in the study eye that would preclude adequate observation with fundus photography/FA or SD-OCT
- •Intraocular surgery in the study eye within 3 months prior to screening
- •Aphakia or total absence of the posterior capsule (yttrium aluminum garnet (YAG) laser capsulotomy permitted, a minimum of 1 month prior to enrollment) in the study eye
研究组 & 干预措施
Active
Experimental
ALK4290 800 mg daily
干预措施: ALK4290 (Drug)
结局指标
主要结局
Best Corrected Visual Acuity (BCVA)
时间窗: Baseline to 6 weeks
Mean change in BCVA letter score as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) method. The ETDRS chart assesses changes in vision based on the number of letters correctly read by the subject.
次要结局
- Incidence of Treatment-emergent Adverse Events (Safety)(Baseline to 10 weeks)
研究者
研究点 (5)
Loading locations...
相似试验
已完成
1 期
Single Ascending Dose Study of ALA-1000Opioid-use DisorderNCT04122755Alar Pharmaceuticals Inc.59
撤回
2 期
Study of FP-1039 in Subjects With Endometrial CancersEndometrial Cancers With FGFR2 MutationsNCT01244438Five Prime Therapeutics, Inc.
已完成
2 期
Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4Chronic Kidney DiseaseNCT04707573Akebia Therapeutics22
招募中
1 期
U87 CAR-T in Patients With Advanced Head and Neck TumorsNasopharynx CancerHead and Neck CancerNCT06614686Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd20
已完成
1 期
Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With SchizophreniaPsychotic DisordersSchizophreniaNCT00821600Johnson & Johnson Pharmaceutical Research & Development, L.L.C.24